Gender-neutral language is increasingly being adopted across different industries, including in certain health care and pharmaceutical communications, to be more inclusive towards a wider range of people. By using terms such as “individuals with a prostate” or “patients with breast cancer,” the communications in question are aiming to consider the experiences of transgender individuals, whose gender identity is different to their physical sex.
How Can Pharma Seek To Discuss Gender Diversity?
Communications Ought To Be Both Accessible And Inclusive
As gender-neutral language becomes more widely used throughout the business community, the pharmaceutical industry must confront how it approaches the matter of gendered language in healthcare communications.
More from Diversity & Inclusion
• By
Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.
• By
Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.
• By
As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment.
• By
The US FDA’s Office of Women’s Health provides a research roadmap to address health concerns specific to women. The FDA recently updated the roadmap, outlining areas in which further research is needed.
More from ESG
• By
The US FDA’s Office of Women’s Health provides a research roadmap to address health concerns specific to women. The FDA recently updated the roadmap, outlining areas in which further research is needed.
• By
As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.
• By
Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.